Abbate Mauro, Zoja Carla, Morigi Marina, Rottoli Daniela, Angioletti Stefania, Tomasoni Susanna, Zanchi Cristina, Longaretti Lorena, Donadelli Roberta, Remuzzi Giuseppe
Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo, Italy.
Am J Pathol. 2002 Dec;161(6):2179-93. doi: 10.1016/s0002-9440(10)64495-1.
Chronic diseases of the kidney have a progressive course toward organ failure. Common pathway mechanisms of progressive injury, irrespectively of the etiology of the underlying diseases, include glomerular capillary hypertension and enhanced passage of plasma proteins across the glomerular capillary barrier because of impaired permselective function. These changes are associated with podocyte injury and glomerular sclerosis. Direct evidence for causal roles is lacking, particularly for the link between intraglomerular protein deposition and sclerosing reaction. Because transforming growth factor-beta1 (TGF-beta1) is the putative central mediator of scarring, we hypothesized that TGF-beta1 can be up-regulated by protein overload of podocytes thereby contributing to sclerosis. In rats with renal mass reduction, protein accumulation in podocytes as a consequence of enhanced transcapillary passage preceded podocyte dedifferentiation and injury, increase in TGF-beta1 expression in podocytes, and TGF-beta1-dependent activation of mesangial cells. Angiotensin-converting enzyme inhibitor prevented both accumulation of plasma proteins and TGF-beta1 overexpression in podocytes and sclerosis. Albumin load on podocytes in vitro caused loss of the synaptopodin differentiation marker and enhanced TGF-beta1 mRNA and protein. Conditioned medium of albumin-stimulated podocytes induced a sclerosing phenotype in mesangial cells, an effect mimicked by TGF-beta1 and blocked by anti-TGF-beta1 antibodies. Thus, the passage of excess plasma proteins across the glomerular capillary wall is the trigger of podocyte dysfunction and of a TGF-beta1-mediated mechanism underlying sclerosis. Agents to reduce TGF-beta1, possibly combined with angiotensin blockade, should have priority in novel approaches to treatment of progressive nephropathies.
慢性肾病会逐渐发展至器官衰竭。无论潜在疾病的病因如何,渐进性损伤的共同途径机制包括肾小球毛细血管高压以及由于滤过选择功能受损导致血浆蛋白跨肾小球毛细血管屏障的通透性增加。这些变化与足细胞损伤和肾小球硬化相关。目前尚缺乏因果关系的直接证据,尤其是肾小球内蛋白质沉积与硬化反应之间的联系。由于转化生长因子-β1(TGF-β1)被认为是瘢痕形成的主要介质,我们推测TGF-β1可因足细胞蛋白过载而上调,从而导致硬化。在肾质量减少的大鼠中,由于跨毛细血管通透性增加导致足细胞内蛋白质积聚先于足细胞去分化和损伤、足细胞中TGF-β1表达增加以及系膜细胞的TGF-β1依赖性激活。血管紧张素转换酶抑制剂可防止血浆蛋白积聚、足细胞中TGF-β1过表达以及硬化。体外给予足细胞白蛋白负荷会导致突触素分化标志物丧失,并增强TGF-β1 mRNA和蛋白表达。白蛋白刺激的足细胞条件培养基可诱导系膜细胞出现硬化表型,TGF-β1可模拟该效应,而抗TGF-β1抗体可阻断该效应。因此,过量血浆蛋白跨肾小球毛细血管壁的通过是足细胞功能障碍和TGF-β1介导的硬化机制的触发因素。降低TGF-β1的药物,可能联合血管紧张素阻断,应成为治疗进行性肾病新方法的优先选择。